Edition:
United Kingdom

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

7,573JPY
12:17am GMT
Change (% chg)

¥26 (+0.34%)
Prev Close
¥7,547
Open
¥7,548
Day's High
¥7,597
Day's Low
¥7,531
Volume
84,300
Avg. Vol
1,361,252
52-wk High
¥7,739
52-wk Low
¥5,200

Latest Key Developments (Source: Significant Developments)

SHIONOGI increases voting power in UMN Pharma to 20.3 pct
Wednesday, 31 Oct 2018 

Oct 31(Reuters) - UMN Pharma Inc <4585.T>:Says SHIONOGI & CO LTD <<<4507.T>>> increases voting power in UMN Pharma to 20.3 percent from 4.7 percent, effective Oct. 31 .  Full Article

R&I affirms Shionogi's rating at "A+" and changes outlook to positive -R&I
Friday, 26 Oct 2018 

Oct 26(Reuters) - Shionogi & Co Ltd <4507.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Rating outlook changes to positive from stable -R&I.  Full Article

Shionogi announces FDA approval of Baloxavir Marboxil for treatment of acute, uncomplicated influenza
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Shionogi & Co Ltd <4507.T>:Says the company announced today that, after completing a priority review, the United States Food and Drug Administration (FDA) has approved XOFLUZATM(baloxavir marboxil) for the treatment of acute, uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.  Full Article

U.S. FDA Says Granted Approval Of New Influenza Drug To Shionogi & Co
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES NEW DRUG TO TREAT INFLUENZA.FDA - APPROVED XOFLUZA FOR TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 12 YRS & OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 48 HOURS.FDA - GRANTED APPROVAL OF XOFLUZA TO SHIONOGI & CO.  Full Article

Shionogi announces U.S. availability of Mulpleta®
Friday, 31 Aug 2018 

Aug 31(Reuters) - Shionogi & Co Ltd <4507.T>:Says it announced today that Mulpleta® (lusutrombopag), for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure, is now available throughout the U.S..  Full Article

Shionogi Announces FDA Approval Of Mulpleta (Lusutrombopag)
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Shionogi & Co Ltd <4507.T>::SHIONOGI ANNOUNCES FDA APPROVAL OF MULPLETA® (LUSUTROMBOPAG).SHIONOGI - FDA APPROVED MULPLETA FOR TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE SCHEDULED TO UNDERGO A PROCEDURE.  Full Article

Shionogi & Co Ltd Says To Buy Back Up To 2.7 Percent Of Own Shares Worth 50 Billion Yen
Monday, 30 Jul 2018 

July 30 (Reuters) - Shionogi & Co Ltd <4507.T>::SHIONOGI & CO LTD SAYS TO BUY BACK UP TO 2.7 PERCENT OF OWN SHARES WORTH 50 BILLION YEN.  Full Article

Shionogi & Co Regains Full Rights To Symproic In US
Monday, 9 Jul 2018 

July 9 (Reuters) - Shionogi & Co Ltd <4507.T>::SHIONOGI REGAINS FULL RIGHTS TO SYMPROIC (NALDEMEDINE) IN US.EFFECTIVE IMMEDIATELY, SHIONOGI HAS REGAINED FULL RIGHTS TO SYMPROIC (NALDEMEDINE) TABLETS 0.2 MG IN UNITED STATES.CO HAS BEGUN OWN SALES AND DISTRIBUTION OF SYMPROIC, IN PROCESS OF SEEKING A NEW PARTNER WITH STRONG COMMERCIAL CAPABILITIES.SHIONOGI AND PURDUE PHARMA LP HAVE AGREED TO TERMINATE PRIOR ALLIANCE FOR U.S. CO-COMMERCIALIZATION OF SYMPROIC.SHIONOGI HAS NO RESIDUAL FINANCIAL OR OTHER OBLIGATIONS TO PURDUE.  Full Article

ROHTO PHARMACEUTICAL says capital alliance with SHIONOGI HEALTHCARE
Monday, 25 Jun 2018 

June 25 (Reuters) - ROHTO PHARMACEUTICAL Co Ltd <4527.T> ::Says it signed an agreement with SHIONOGI HEALTHCARE & Co Ltd, to form a capital alliance .Says the company will acquire around 15 percent stake in SHIONOGI HEALTHCARE from its parent company SHIONOGI & CO LTD <<<4507.T>>>.  Full Article

PeptiDream says completion of technology transfer of Peptide Discovery Platform System to Shionogi
Thursday, 17 May 2018 

May 17 (Reuters) - PeptiDream Inc <4587.T>:Says co completed the transfer of co's proprietary Peptide Discovery Platform System (PDPS) technology to Shionogi & Co Ltd <<<4507.T>>>.Under the terms of the nonexclusive license agreement entered into by the co and Shionogi in June 2017, co will receive an undisclosed milestone payment and is eligible to receive additional technology access payments, in addition to payments based on achievement of certain predetermined development milestones for any constrained peptides and/or small molecules discovered from use of the PDPS technology.In addition, co is eligible to receive royalties on sales of certain products that arise from use of the PDPS technology .  Full Article

Long-lasting HIV injection is a step closer after second GSK study

LONDON, Oct 30 A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients to be filed with regulators.